Get the Stockscreener App
11.90
0.00%
0.00
After Hours:
11.91
0.010
+0.08%
Alvotech stock is traded at $11.90, with a volume of 25,170.
It is up +0.00% in the last 24 hours and up +1.88% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
See More
Previous Close:
$11.90
Open:
$11.99
24h Volume:
25,170
Relative Volume:
0.25
Market Cap:
$3.59B
Revenue:
$306.77M
Net Income/Loss:
$-618.38M
P/E Ratio:
-6.0406
EPS:
-1.97
Net Cash Flow:
$-343.00M
1W Performance:
+9.37%
1M Performance:
+1.88%
6M Performance:
-2.62%
1Y Performance:
+30.48%
1-Day Range:
$11.84
$11.99
1-Week Range:
$10.87
$11.99
52-Week Range:
$8.30
$18.00
Alvotech Stock (ALVO) Company Profile
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Wall Street SWOT: Alvotech stock rises as biosimilar powerhouse gains momentum - Investing.com India
Wall Street SWOT: Alvotech stock rises as biosimilar powerhouse gains momentum - Investing.com Canada
Alvotech (ALVO) Stock Price Up 3.79% on Sep 27 - GuruFocus.com
Alvotech (NASDAQ:ALVO) Shares Sold by Sculptor Capital LP - MarketBeat
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® - GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT16 - Marketscreener.com
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® - StockTitan
Alvotech : Registration Statement Declared Effective - Marketscreener.com
EMA Accepts Marketing Authorization Application For Alvotech's AVT06 (Aflibercept) - Marketscreener.com
Alvotech (NASDAQ:ALVO) Short Interest Up 108.1% in August - MarketBeat
Alvotech : Filing of a Request with the SEC - Marketscreener.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT06 (aflibercept) - JD Supra
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Yahoo Finance
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Marketscreener.com
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - StockTitan
Alvotech: Steady Progress Offers Good Chance Of Upside (ALVO) - Seeking Alpha
Alvotech : Filing of a Preliminary Prospectus with the SEC - Marketscreener.com
Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024 - The Center for Biosimilars
Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023) - Simply Wall St
Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023) - Yahoo Finance
Alvotech (NASDAQ:ALVO) Issues Earnings Results, Beats Estimates By $0.56 EPS - MarketBeat
Alvotech (NASDAQ:ALVO) Short Interest Down 11.5% in July - MarketBeat
When Will Alvotech (NASDAQ:ALVO) Become Profitable? - Simply Wall St
Earnings call: Alvotech sees tenfold revenue increase, bullish on biosimilars By Investing.com - Investing.com Australia
Citi keeps Alvotech stock at Neutral, maintains PT amid bHumira growth - Investing.com Canada
Earnings call: Alvotech sees tenfold revenue increase, bullish on biosimilars - Investing.com
Earnings call: Alvotech sees tenfold revenue increase, bullish on biosimilars By Investing.com - Investing.com UK
Citi keeps Alvotech stock at Neutral, maintains PT amid bHumira growth - Investing.com
AlvotechEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea - Marketscreener.com
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 - wallstreet:online
Alvotech : Unaudited Consolidated Financial Statement Q2 2024 - Marketscreener.com
ALVO Stock Earnings: Alvotech Misses Revenue for Q2 2024 - MSN
Alvotech’s biosimilar to Regeneron’s Eylea under EU review - MSN
Alvotech Achieved Record Revenue in Q2 and Turned Profitable - Sigorta Haber
Alvotech Reports Revenue Surge Amidst Expansion - TipRanks
Alvotech reports record revenue, swings to profit in Q2 By Investing.com - Investing.com Australia
Alvotech reports record revenue, swings to profit in Q2 By Investing.com - Investing.com India
Alvotech reports record revenue, swings to profit in Q2 - Investing.com
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 - GlobeNewswire
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 - StockTitan
Alvotech stock gains on EU review for Eylea rival (NASDAQ:ALVO) - Seeking Alpha
Alvotech’s Biosimilar AVT06 Eyes European Market - TipRanks
European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - Yahoo Finance UK
Alvotech (NASDAQ:ALVOW) Short Interest Up 450.0% in July - Defense World
Vanguard Group Inc. Purchases 63,948 Shares of Alvotech (NASDAQ:ALVO) - MarketBeat
Vanguard Group Inc. Boosts Holdings in Alvotech (NASDAQ:ALVO) - Defense World
Alvotech (NASDAQ:ALVOW) Shares Up 1.1% - Defense World
Alvotech (ALVO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Alvotech (ALVO) to Release Quarterly Earnings on Thursday - Defense World
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):